A Phase III study to compare Apatinib plus BSC with placebo plus BSC

• Research type

  Research Study

• Full title

  A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care (BSC) compared to Placebo plus BSC in Patients with Advanced or Metastatic Gastric Cancer (GC)

• IRAS ID

  218262

• Contact name

  Ian Chau

• Contact email

  Ian.Chau@rmh.nhs.uk

• Sponsor organisation

  LSK BioPartners, Inc

• Eudract number

  2016-003984-20

• Clinicaltrials.gov Identifier

  NCT03042611

• Duration of Study in the UK

  1 years, 3 months, 29 days

• Research summary

  The aim of this study is to assess the the safety and the effectiveness of Apatinib when it is given to patients to treat Advanced or Metastatic Gastric Cancer, comparing Apatinib plus Best Supportive Care against a placebo plus Best Supportive Care.

• REC name

  East of England - Essex Research Ethics Committee

• REC reference

  17/EE/0384

• Date of REC Opinion

  11 Dec 2017

• REC opinion

  Further Information Favourable Opinion